Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. [electronic resource]
Producer: 20080409Description: 549-58 p. digitalISSN:- 0344-5704
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Boronic Acids -- therapeutic use
- Bortezomib
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Cisplatin -- pharmacology
- Drug Evaluation, Preclinical
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Flow Cytometry
- Genes, Intracisternal A-Particle -- drug effects
- Glutamates -- pharmacology
- Guanine -- analogs & derivatives
- Humans
- Mesothelioma -- drug therapy
- Neoplasm Proteins -- biosynthesis
- Pemetrexed
- Pleural Neoplasms -- drug therapy
- Proteasome Inhibitors
- Pyrazines -- therapeutic use
- Survival Analysis
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.